PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan

PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics^®, a subsidiary of Interpace Biosciences^®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced notification that the Centers for Medicare & Medicaid Services (CMS) directed its Medicare Administrative Contractors, Novitas and First Coast Service Options, Inc., to delay implementation of the Genetic Testing for Oncology Local Coverage Determination (LCD) (L39365), from February 23, 2025, to April 24, 2025.

Read more at globenewswire.com